Paloma Partners’s Titan Pharmaceuticals TTNP Stock Holding History

Paloma Partners’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20	Closed	-$136K	–	2439
2017 Q2	$136K	Buy	+20	New	+$186K	﹤0.01%	2051

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paloma Partners's TTNP Position: Q3 2017 in Review

Paloma Partners sold out of Titan Pharmaceuticals (TTNP) in Q3 2017, closing a stake of 20 shares — an estimated $136K sold.

Paloma Partners first reported a position in TTNP in Q2 2017 and held it in 1 quarter. The position peaked at $136K in Q2 2017. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

Paloma Partners reported no remaining Titan Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 20 Titan Pharmaceuticals shares in Q3 2017, an estimated $136K.
Paloma Partners first reported a position in Titan Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Paloma Partners's Titan Pharmaceuticals position peaked at $136K in Q2 2017.
24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.